Details

Autor(en) / Beteiligte

• Qin, Yuanyuan
• Zhou, Yihong
• Liu, Songtao
• Lu, Yanqiu
• Liu, Min
• Yuan, Jing
• Nie, Jingmin
• Ouyang, Jing
• Wu, Hao
• Qin, Yingmei
• Jiang, Zhongsheng
• Zhou, Guoqiang
• Tian, Qun
• Lan, Ke
• Zhou, Yang
• Yang, Xinping
• He, Kaiyin
• Liu, Jun
• Harypursat, Vijay
• Chen, Yaokai

Titel

HIV-associated talaromycosis: Does timing of antiretroviral therapy matter?

Ist Teil von

• The Journal of infection, 2022-03, Vol.84 (3), p.410-417

Ort / Verlag

England: Elsevier Ltd

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• : No current academic data is available with respect to the optimal timing to initiate antiretroviral therapy (ART) in HIV-positive patients with talaromycosis. Our study aimed to evaluate the optimal timing of ART initiation for patients presenting with AIDS-related talaromycosis. : In this prospective, randomized, open-label multicenter trial, 228 patients from 15 hospitals in China were randomly assigned to an early ART group (initiation of ART within 2 weeks after randomization) and a deferred ART group (initiation of ART 2 weeks after randomization). The primary endpoint was all-cause mortality during the 48 weeks after randomization. : We observed a significant difference in mortality between the early ART group and the deferred ART group (2.2% vs. 8.9%, 95%CI: -0.15 to 14.05, p = 0.049). The composite outcome of AIDS-defining events or death in the early ART group was found to be lower than that in the deferred ART group (3.3% vs. 14.9%; 95%CI: 2.93 to 19.23, p = 0.008). : The prognosis of HIV-infected patients with talaromycosis in the early ART group was more favorable than that of patients in the deferred ART group. These results demonstrate that early ART initiation should be considered in HIV-infected patients with talaromycosis .